ଫ୍ଲୋରେସିନ (ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର)

Fluorescein
	Fluorescein drops being put in the eye before examination
Clinical data
Pronunciation	FLURE-a-seen
Trade names	Fluorescite, AK-Fluor, BioGlo, others
data	US DailyMed: Fluorescein;
Routes of; administration	Eye drops, intravenous, by mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Identifiers
	IUPAC name 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one;
Chemical and physical data
Formula	C20H12O5
Molar mass	୩୩୨.୩୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O;
	InChI InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H; Key:GNBHRKFJIUUOQI-UHFFFAOYSA-N;

ଫ୍ଲୋରେସିନ (ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର) ଅନେକ ଚକ୍ଷୁ ରୋଗ ନିର୍ଣ୍ଣୟ କରିବାରେ ସାହାଯ୍ୟ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୨] ବୁନ୍ଦା ବା ଏକ କାଗଜ ଷ୍ଟ୍ରିପ୍ ମାଧ୍ୟମରେ ଆଖିର ପୃଷ୍ଠରେ ପ୍ରୟୋଗ କରାଯାଇ ଆଖିର ଆଘାତ ଯେପରିକି ବାହ୍ୟ ପଦାର୍ଥ (foreign bodies) ଓ କର୍ଣ୍ଣିଆଲ୍ ଆବ୍ରାଜନ ଚିହ୍ନଟ କରିବାରେ ସାହାଯ୍ୟ କରେ | ^[୩] ^[୪] ଫ୍ଲୋରେସିନ ଆଞ୍ଜିଓଗ୍ରାଫି ସମୟରେ ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ ଆକାରରେ ଦେଇ ରକ୍ତନଳୀ ସମସ୍ୟା ଆକଳନ କରିବାରେ ସାହାଯ୍ୟ ହୁଏ | ^[୫] ^[୬]

ଆଖିରେ ପ୍ରୟୋଗ କଲେ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କିଛି ସମୟ ପାଇଁ ଝାପସା ଦେଖାଯାଏ ଓ କଣ୍ଟାକ୍ଟ ଜବକାଚ ରଙ୍ଗ ବଦଳେ । ^[୭]^[୨] ପାଟିରେ ବା ଇଞ୍ଜେକସନ ଆକାରରେ ଦେଲେ ମୁଣ୍ଡ ବିନ୍ଧା, ଅଇ ଓ ଅଳ୍ପ ସମୟ ପାଇଁ ରର୍ମର ରଙ୍ଗ ବଦଳିଯାଏ । କ୍ୱଚିତ ଆଲର୍ଜି ହୋଇପାରେ । ଫ୍ଲୋରେସିନ ଏକ ରଙ୍ଗ ଯାହାକୁ କ୍ଷତିଗ୍ରସ୍ତ କର୍ଣ୍ଣିଆ ଗ୍ରହଣ କରିବା ପରେ କୋବାଲ୍ଟ ନୀଳ ଆଲୋକରେ ଶାଗୁଆ ଦେଖାଯାଏ । ଲିଡୋକେନ୍ ମିଶ୍ରିତ ଫ୍ଲୋରେସିନ ମଧ୍ୟ ମିଳେ ।^[୩]^[୮]

ଫ୍ଲୋରେସେନ୍ ପ୍ରଥମେ ୧୮୭୧ ମସିହାରେ ତିଆରି ହୋଇଥିଲା |^[୯] ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଅଛି ।^[୧୦] ବିକାଶଶୀଳ ଦେଶମାନଙ୍କରେ ବିକାଶଶୀଳ ଦେଶମାନଙ୍କରେ ଏହାର ହୋଲସେଲ ମୂଲ୍ୟ 5୫ମିଲି ବୋତଲ ପିଛା ପ୍ରାୟ ୧୨.୨୫ ଡଲାର ଅଟେ |^[୧୧] ଯୁକ୍ତରାଜ୍ୟରେ ଗୋଟିଏ ଡୋଜ୍ର ମୂଲ୍ୟ ପ୍ରାୟ ୦.୪୩ ପାଉଣ୍ଡ | ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ମଧ୍ୟ ମହଙ୍ଗା ନୁହେଁ। ^[୪]

ଆଧାର

↑ "Fluorescein sodium 100 mg/ml, solution for injection - Summary of Product Characteristics (SmPC)". (emc). 16 January 2018. Archived from the original on 28 August 2021. Retrieved 11 March 2020.
↑ ^୨.୦ ^୨.୧ Duvall, Brian; Kershner, Robert M. (2006). Ophthalmic Medications and Pharmacology (in ଇଂରାଜୀ). SLACK Incorporated. p. 29. ISBN 9781556427503. Archived from the original on 2017-01-18.
↑ ^୩.୦ ^୩.୧ ^୩.୨ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. pp. 769, 772. ISBN 9780857111562.
↑ ^୪.୦ ^୪.୧ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 416. ISBN 9781284057560.
↑ Duvall, Brian; Kershner, Robert M. (2006). Ophthalmic Medications and Pharmacology (in ଇଂରାଜୀ). SLACK Incorporated. p. 29. ISBN 9781556427503. Archived from the original on 2017-01-18.
↑ "Anatera 100mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 10 February 2020. Archived from the original on 5 August 2020. Retrieved 11 March 2020.
↑ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 314. hdl:10665/44053. ISBN 9789241547659.
↑ "Minims Lidocaine & Fluorescein Summary of Product Characteristics (SmPC) - (emc)". (emc). 23 October 2017. Archived from the original on 20 September 2020. Retrieved 11 March 2020.
↑ Bartlett, Jimmy D.; Jaanus, Siret D. (2008). Clinical Ocular Pharmacology (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 283. ISBN 0750675764. Archived from the original on 2017-01-18.
↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Fluorescein_SmPC-1] "Fluorescein sodium 100 mg/ml, solution for injection - Summary of Product Characteristics (SmPC)". (emc). 16 January 2018. Archived from the original on 28 August 2021. Retrieved 11 March 2020.

[Du2006-2] ୨.୦ ^୨.୧ Duvall, Brian; Kershner, Robert M. (2006). Ophthalmic Medications and Pharmacology (in ଇଂରାଜୀ). SLACK Incorporated. p. 29. ISBN 9781556427503. Archived from the original on 2017-01-18.

[BNF69-3] ୩.୦ ^୩.୧ ^୩.୨ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. pp. 769, 772. ISBN 9780857111562.

[Ric2015-4] ୪.୦ ^୪.୧ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 416. ISBN 9781284057560.

[autogen2-5] Duvall, Brian; Kershner, Robert M. (2006). Ophthalmic Medications and Pharmacology (in ଇଂରାଜୀ). SLACK Incorporated. p. 29. ISBN 9781556427503. Archived from the original on 2017-01-18.

[6] "Anatera 100mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 10 February 2020. Archived from the original on 5 August 2020. Retrieved 11 March 2020.

[WHO2008-7] World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 314. hdl:10665/44053. ISBN 9789241547659.

[8] "Minims Lidocaine & Fluorescein Summary of Product Characteristics (SmPC) - (emc)". (emc). 23 October 2017. Archived from the original on 20 September 2020. Retrieved 11 March 2020.

[9] Bartlett, Jimmy D.; Jaanus, Siret D. (2008). Clinical Ocular Pharmacology (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 283. ISBN 0750675764. Archived from the original on 2017-01-18.

[WHO21st2-10] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[WHO21st-11] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[୨]

[୩]

[୪]

[୫]

[୬]

[୧]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]